Sjögren's disease & overlap diseases
The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjögren's disease: a monocentric cohort study
Authors' conclusion
RTX is an effective and safe treatment to control Sjögren-CryoVasc disease activity with a greater impact when administered earlier with a maintenance regimen. RTX alone cannot, however, affect the possible evolution of Sjögren-CryoVasc into an overt NHL.
Study context
- Population
- Patients with cryoglobulinaemic vasculitis secondary to Sjögren's disease (Sjögren-CryoVasc)
- Participants
- 13 patients
- Exposure
- Early rituximab (RTX) induction with maintenance vs late RTX induction with possible on-demand retreatment vs no RTX
- Early RTX + maintenancen = 5
- Late RTXn = 5
- No RTXn = 3reference
- Outcome
- Change in cumulative ESSDAI (vasculitic- and lymphoproliferative-related domains)
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
- Both RTX groups showed a decrease in ESSDAI, with Early RTX + maintenance showing the most substantial reduction
- p=0.028
Observational data: associations, not effects.
Further findings
Vasculitic-related ESSDAI domains (cutaneous, PNS, articular), RTX-treated patients
- Significant improvement in cutaneous domain
- P = 0.007
- Significant improvement in PNS domain
- P = 0.006
- Significant improvement in articular domain
- P = 0.03
Lymphoproliferative-related ESSDAI domains
- Improvement in glandular domain, Early RTX + maintenance
- P = 0.03
- Improvement in nodal domain, Early RTX + maintenance
- P = 0.03
- RTX did not greatly affect lymphoproliferative-related domains
Non-Hodgkin lymphoma (NHL) occurrence
- No differences between the groups
Safety
Safety concerns (incl. persistent hypogammaglobulinaemia with serious infections)
- No differences in safety concerns between the groups
Original publication
The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjögren's disease: a monocentric cohort study. Clin Exp Rheumatol. Published 2 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →